REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > O-glycoside > > Nitrogen Containing Hetero Ring > Pyrimidines (including Hydrogenated) (e.g., Cytosine, Etc.) Pyrimidines (including Hydrogenated) (e.g., Cytosine, Etc.)Pyrimidines (including Hydrogenated) (e.g., Cytosine, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/18/07 - 20070015728 - Metered-dose and safety and compliance packaging for systemic anticancer therapy The invention provides a metered-dose package for coadministration of a first and a second component of a therapeutic agent. The metered-dose package includes a first plurality of fluidly noncommunicating chambers, each chamber sealably containing an individual dose of the first component, and a second plurality of chambers, each said chamber ... 01/18/07 - 20070015727 - Delivery of modulators of glutamate-mediated neurotransmission to the inner ear The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus. ... 01/11/07 - 20070010479 - Compositions and methods for treatment of mitochondrial diseases Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies. ... 01/11/07 - 20070010478 - Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML). ... 01/11/07 - 20070010477 - Acyl homoserine lactones for inhibition of cell growth The present invention provides a method for inhibiting the growth of cancer cells using AHLs of the general formula CX-homoserine lactone where “X” represents a number of between 5 and 14 carbon atoms in the acyl chain of the AHL. The method comprises the step of administering to an individual ... 01/04/07 - 20070004670 - Compositions containing citicoline, and methods of use thereof The present invention is directed to methods of improving memory, learning, cognition, synaptic transmission, and synthesis and release of neurotransmitters and increasing brain phospholipid levels in a subject, comprising administering to the subject a CDP-choline or a pharmaceutically acceptable salt thereof. ... 11/16/06 - 20060258614 - Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide pyrimidine-based ... 10/26/06 - 20060241078 - Pharmaceutical compositions comprising a contraceptive agent in solution and a teratogen The present invention relates to pharmaceutical compositions comprising an estrogen and a progestin in solution, and a teratogen suspended in the estrogen and progestin solution. The present invention also relates to methods of making and using the pharmaceutical compositions described herein. ... 10/26/06 - 20060241077 - Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same The present invention is directed to methods of ameliorating hippocampal dysfunction and improving or inhibiting decline in intelligence or cognitive or hippocampal-dependent memory of a subject and of increasing synthesis and release of neurotransmitters, neurite outgrowth, and levels of neurofilament proteins in the brain and CNS of a subject, comprising ... 10/12/06 - 20060229275 - Production method of 2-deoxy-l-ribofuranosyl chloride compound 2-Deoxy-L-ribofuranosyl chloride compounds may be produced on an industrial scale by dehalogenating a 2-deoxy-2-halo-L-arabinofuranose compound to give a 2-deoxy-L-ribofuranose compound, and then reacting this compound with a chlorinating agent. ... 10/05/06 - 20060223780 - Method for administration of capecitabine There is provided a new dosage regimen for capecitabine which maximizes anti-tumor activity while maintaining acceptable toxicity levels. ... 09/28/06 - 20060217345 - Beta-l-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases Nucleoside analogs, nucleic acids and pharmaceutical agents comprising same, and to the use of said nucleoside analogs, nucleic acids and pharmaceutical agents in the diagnosis, prophylaxis or therapy of a viral, bacterial, fungicidal and/or parasitic infection, or of cancer, particularly of hepatitis infections. The invention also relates to a method ... 08/24/06 - 20060189565 - Pharmaceutical compositions of ganciclovir The technical field of the invention relates to pharmaceutical compositions of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir) that are stable and contain more than 1% water content. One pharmaceutical composition includes ganciclovir having more than about 1% water content, and one or more pharmaceutically acceptable excipients. The ganciclovir retains at least about 97% ... 07/27/06 - 20060166926 - Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases The invention encompasses nucleoside compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions. ... 07/13/06 - 20060154892 - Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also ... 07/13/06 - 20060154891 - Ready-to-use gemcitabine solutions and gemcitabin concentrates Pharmaceutical compositions in the form of ready-to-use preparations of gemcitabine in aqueous solutions in a glass containers having specified dimensional relationships demonstrate long shelf life over a wide range of solution pH values. The ratio of the surface area of the container wetted by the solution to the volume of ... 07/06/06 - 20060148753 - Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU ... 06/29/06 - 20060142240 - Mutagenic nucleoside analogs for the treatment of viral disease The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs. ... 06/29/06 - 20060142239 - Potassium or sodium salt of (-)-2-(4-hydroxyphenyl)ethyl!-thio-3-'4-{4-'(methzlsulfonzl)oxy !phenoxy}phenyl!propanoic acid and their use in medicine A method for the production of a vascular damaging effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer involving a solid tumour, such as colorectal cancer, which comprises one of: the administration of ... 06/29/06 - 20060142238 - Chemical compounds Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may be substituted at the 5-position. The phosphoramidate moiety has attached to the P atom an aryl-O moiety and an α-amino acid moiety. ... 06/22/06 - 20060135468 - Treatment of refractory cancers using na+/k+ atpase inhibitors The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na+/K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain or proscillaridin, etc.). ... 06/15/06 - 20060128654 - Pharmaceutical formulation of cytidine analogs and derivatives The present invention provides pharmaceutical formulations of cytidine analogs and derivatives, such as 5-azacytidine, 5-aza-2′-deoxy-2′,2′-difluorocytidine, 5-aza-2′-deoxy-2′-fluorocytidine, 2′-deoxy-2′,2′-difluorocytidine, and cytosine 1-β-D-arabinofuranoside, as well as methods of manufacturing the formulations. In particular, the cytidine analog or derivative is formulated with a cyclodextrin compound to stabilize and/or enhance solubility of the drug. Kits ... 06/15/06 - 20060128653 - Pharmaceutical formulation of decitabine The present invention provides pharmaceutical formulations of decitabine or 5-aza-2′-deoxycytidine as well as methods of manufacturing the formulations. In particular, decitabine is formulated with a cyclodextrin compound to stabilize and/or enhance solubility of the drug. Kits and methods for using the pharmaceutical formulations are also provided, including methods of administering ... 06/08/06 - 20060122146 - Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives The present invention provides (i) processes for preparing a 2′-deoxy-2′-fluoro-2′-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2′-deoxy-2′-fluoro-2′-C-methyl-β-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside. ... 06/01/06 - 20060116345 - Antitumor effect potentiator and antitumor agent The present invention provides an antitumor effect potentiator for enhancing antitumor activity of an antitumor agent comprising tegafur in a therapeutically effective amount, gimeracil in an amount effective for enhancing an antitumor effect, and oteracil potassium in an amount effective for inhibiting a side effect, the antitumor effect potentiator comprising ... 05/04/06 - 20060094685 - Medicinal composition for drug-induced neuropathy The present invention relates to an agent for the prophylaxis or treatment of drug-induced neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of drug-induced neuropathy of the present invention shows a potent ameliorating effect on drug-induced neuropathy and is also superior ... 04/27/06 - 20060089329 - Ready-to-use gemcitabine solution concentrates Provided are ready-to-use pharmaceutical compositions in the form of gemcitabine solution concentrates. ... 04/27/06 - 20060089328 - Ready-to-use gemcitabine solutions Provided are ready-to-use pharmaceutical compositions in the form of gemcitabine solutions. ... 04/27/06 - 20060089327 - Combinations comprising epothilones and anti-metabolites Disclosed is a combination which comprises (a) an antineoplastic antimetabolite and (b) an epothilone derivative of formula (I), wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R′ is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z ... 04/20/06 - 20060084628 - Combination therapy for treating viral infections A method of treating viral infections, particularly Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) infections, by administering Elvucitabine and a second active agent to a patient suffering viral infection is provided herein. The second active agent is, for example, an immunomodulatory compound, an anti-viral agent, or a combination comprising ... 04/20/06 - 20060084627 - Synergistic interaction of abacavir and alovudine A pharmaceutical preparation comprising a synergistic combination of abacavir and alovudine and a pharmaceutical carrier therefor. Use of abacavir and alovudine together for the treatment of multiresistant HIV, wherein the use comprises simultaneous, combined or sequential administration of alovudine and abacavir. ... 04/06/06 - 20060074047 - Method of treating inflammation with inhibitors of sialyl transferases Provided herein are a methods of reducing a level of activity of a sialyl transferase enzyme, a sialidase enzyme or a combination thereof using inhibitors of these enzymes, for example specific inhibitory compound or antibodies directed against the enzymes. The methods are effective to treat an inflammatory disease or disorder ... 04/06/06 - 20060074046 - Oral administration of decitabine salt The present invention relates to salts of decitabine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the decitabine salts are also provided, including methods of orally administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders. ... 03/30/06 - 20060069060 - Salts of decitabine The present invention relates to salts of decitabine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the decitabine salts are also provided, including methods of administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders. ... 03/23/06 - 20060063736 - Compositions and methods for inhibiting mucin-type o-linked glycosylation The present invention provides inhibitors of mucin-type O-linked glycosylation, and in particular inhibitors of polypeptide N-acetyl-α-galactosaminyltransferases; as well as compositions comprising the inhibitors. The present invention further provides methods of identifying inhibitors of polypeptide N-acetyl-α-galactosaminyltransferases. The inhibitors are useful in various applications, including research applications, and treatment methods. ... 03/23/06 - 20060063735 - Salts of 5-azacytidine The present invention relates to salts of 5-azacytidine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the 5-azacytidine salts are also provided, including methods of administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders. ... 03/16/06 - 20060058260 - Combination therapy with gemcitabine and zd6126 The present invention relates to a method for the production of a vascular damaging effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer involving a solid tumour, which comprises the administration of ZD6126 ... 02/23/06 - 20060040890 - Anti-viral nucleosides 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (I:R1=R2=R3=R4=H) and prodrugs thereof are hepatitis C(HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process. ... 01/12/06 - 20060009418 - Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, ... 01/05/06 - 20060003963 - Method for preparation of 2'-deoxy-2', 2'-difluoro-beta-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-beta-d-glucose as raw material The present invention provides a method for preparation of 2′-deoxy-2′,2′-difluoro-β-cytidine or pharmaceutically acceptable salt thereof, comprising starting from 1,6-anhydro-β-D-glucose as raw material, oxidizing, and fluorinating to obtain 2-deoxy-2,2-difluoro-D-ribofuranose as intermediate. The 2′-deoxy-2′,2′-difluoro-β-cytidine was finally prepared from the intermediate of 2-deoxy-2,2-difluoro-D-ribofuranose. The method is simple in operation and has a high ... 12/08/05 - 20050272689 - Methods, compositions, and kits for organ protection during systemic anticancer therapy Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents. ... 12/08/05 - 20050272688 - Combined treatment with gemcitabine and an epidermal growth factor receptor kinase inhibitor The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. ... 12/01/05 - 20050267066 - Pharmaceutical composition comprising a cdk inhibitor and gemcitabine A first aspect of the invention relates to a combination comprising a CDK inhibitor and gemcitabine. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and gemcitabine as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the ... 11/03/05 - 20050245478 - Postoperative adjuvant chemotherapy with uft The present invention provides an improved method for treating lung cancer, preferably non-small cell lung cancer, by orally administering UFT to postoperative lung cancer patients. ... 10/06/05 - 20050222077 - Use of cdp-choline for the prophylactic treatment of cerebral ischemia The invention describes a prophylactic treatment of cerebral ischemia with CDP-Choline in patients who have undergone major surgery or are at risk of suffering an acute ischemic event. ... 09/29/05 - 20050215514 - Treatment method against side-effects of chemotherapy A method and composition is provided for organ rescue wherein a specific counter-measure is applied locally to a tissue at risk for or exhibiting an adverse side effect of a cancer treatment. More particularly, the method and composition is directed at controlling Hand-Foot Syndrome, a painful redness and cracking of ... 09/22/05 - 20050209186 - Method for treating chronic myelogenous leukemia Methods, compositions and kits are provided for treating cancer associated with protein tyrosine kinase activity such as chronic myelogenous leukemia. In particular, a treatment method is provided comprising: administering to a patient having chronic myelogenous leukemia and a degree of resistance to imatinib mesylate, a therapeutically effective amount of a ... 09/01/05 - 20050192247 - Method of treating cancers Cancers and/or malignancies can be treated by administration of a G1/S phase drug, which is preferably β-lapachone, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, combined with an S phase drug, which is advantageously gemcitabine. This combination of a G1/S phase drug with an S phase drug ... 08/25/05 - 20050187184 - Antineoplastic combinations This invention provides the use of a combination of CCI-779 and an antimetabolite antineoplastic agent in the treatment of neoplasms. ... 08/25/05 - 20050187183 - Use of amphiphilic nucleoside phosphonoformic acid derivatives for the treatment of viral infectious diseases The invention relates to a method for treating infectious diseases which are elicited by viruses which are pathogenic to humans comprising the step of administering an amphiphilic nucleoside-phosphonoformic acid derivative having an esterified or unesterified carboxyl group, preferably of a nucleoside-glycerol-(hydroxycarbonyl)-phosphonate, as an active compound. ... 08/25/05 - 20050187182 - Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function The present invention provides methods of improving a cognitive function or a neurological function, treating or ameliorating a decline in a cognitive function or a neurological function, increasing cytidine levels, or treating a neurological disorder in a subject, comprising administering a uridine, a uridine precursor, or a derivative or metabolite ... 08/11/05 - 20050176676 - Uridine administration stimulates membrane production The present invention provides methods of stimulating or enhancing production of a cellular membrane, improving a cognitive function or a neurological function, treating or ameliorating a decline in a cognitive function or a neurological function, increasing cytidine levels, or treating a neurological disorder in a subject, comprising administering a uridine, ... 07/28/05 - 20050164976 - Combination of a cdk inhibitor and 5-fu for the tratment of cancer A first aspect of the invention relates to a combination comprising a CDK inhibitor and 5-FU, or a prodrug thereof. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and 5-FU, or a prodrug thereof, as a combined preparation for simultaneous, sequential or separate ... 07/21/05 - 20050159389 - Combination therapy for treatment of fiv infection The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and ... 07/14/05 - 20050153927 - Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A. ... ### FreshPatents.com Support |